<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429962</url>
  </required_header>
  <id_info>
    <org_study_id>081-PRC-2006-005</org_study_id>
    <nct_id>NCT00429962</nct_id>
  </id_info>
  <brief_title>Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV</brief_title>
  <official_title>Randomized, Phase IIIb Study Comparing Safety, Tolerability and Efficacy Between Lucentis® Administered in Conjunction With PDT With Visudyne® and Lucentis® in Patients With Subfoveal CNV Secondary to Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab&#xD;
      used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab&#xD;
      monotherapy for the treatment of subfoveal CNV secondary to AMD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal ranibizumab has shown to increase average vision in patients with subfoveal CNV&#xD;
      secondary to AMD. However, the treatment does not provide benefit to all patients and the&#xD;
      treatment regimen requires monthly intravitreal injections. Ranibizumab is an anti-VEGF-A&#xD;
      monoclonal antibody fragment. Verteporfin photodynamic therapy acts through occluding newly&#xD;
      formed vessels. The combination of these therapies acting through different modes of action&#xD;
      bears the potential to provide a more convenient and less frequent therapy while&#xD;
      maintaining/improving the increase in vision improvement observed with ranibizumab&#xD;
      monotherapy. The strategic goal is to evaluate whether intravitreal ranibizumab in&#xD;
      combination with verteporfin photodynamic therapy is an effective, safe and convenient&#xD;
      treatment for patients with subfoveal CNV secondary to AMD and explore potential advantages&#xD;
      of such treatment compared to ranibizumab monotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First injection with PDT</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monthly clinical evaluation of safety and necessity of re-intravitreal injection of ranibizumab after three initial injections</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreal ranibizumab used in combination with verteporfin photodynamic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravitreal ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal ranibizumab</intervention_name>
    <description>intraocular injection</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal ranibizumab &amp; photodynamic therapy</intervention_name>
    <description>intraocular injection photodynamic treatment (LASER) after intravenous injection</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Visudyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients over 50 years, subfoveal CNV of any type secondary to age-related macular&#xD;
             degeneration (AMD), no &quot;macula-treatment for the last 30 days (e.g. with PDT, TA,&#xD;
             Laser, Macugen®).&#xD;
&#xD;
               -  the area of the CNV must occupy at least &gt;50% of the lesion (total lesion size&#xD;
                  under 5400 microns in greatest linear dimension)&#xD;
&#xD;
               -  Occult CNV:&#xD;
&#xD;
                    -  recent disease progression&#xD;
&#xD;
                    -  bleeding&#xD;
&#xD;
                    -  VA decreased the last three months &gt;5 letters or 2 or more than two lines&#xD;
                       (Snellen)&#xD;
&#xD;
                    -  10% increase of the lesion size the last three months&#xD;
&#xD;
          2. Best corrected visual acuity score between 24-73 letters (20/40 to 20/320) (ETDRS 4 m)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with mit Laser, PDT, Macugen, TA&#xD;
&#xD;
          2. Prior treatment with radiatio, vitrectomy, transpupillary thermotherapy&#xD;
&#xD;
          3. History of surgical intervention in the study eye within two months preceding day 1&#xD;
&#xD;
          4. concurrent use of systemic anti-VEGF agents&#xD;
&#xD;
          5. previous treatment with or participation in a clinical trial involving anti-angiogenic&#xD;
             drugs (Pegaptanib, ranibizumab, anecortave acetate of corticosteroids).&#xD;
&#xD;
          6. Ocular disorders in the study eye that may confound interpretation of the study&#xD;
             results, including retinal detachment or macular hole (Stage 3 or 4), active&#xD;
             intraocular inflammation (grade trace or above) or persistent macular edema due to&#xD;
             uveitis or other inflammatory diseases&#xD;
&#xD;
          7. Retinal pigment epithelium tear, vitreous hemorrhage or history of rhegmatogenous&#xD;
             retinal detachment or macular hole in the study eye&#xD;
&#xD;
          8. History of idiopathic or autoimmune-associated uveitis in either eye, active&#xD;
             infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye&#xD;
&#xD;
          9. Extracapsular extraction of cataract with phacoemulsification within two months&#xD;
             preceding day 1, or a history of post-operative complications within the last 12&#xD;
             months preceding day 1 or a history of post-operative complications within the last 12&#xD;
             months preceding day 1 in the study eye (uveitis, cyclitis, iritis etc.)&#xD;
&#xD;
         10. Glaucoma with IOP&gt;25 mmHg despite therapy&#xD;
&#xD;
         11. Aphakia or absence of the posterior capsule in the study eye&#xD;
&#xD;
         12. Spherical equivalent &gt;-8&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Schneider, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Eye Clinic Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Eye Clinic</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>January 31, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>April 6, 2009</last_update_submitted>
  <last_update_submitted_qc>April 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Selim Orgul</name_title>
    <organization>University Hospital, Basel, Switzerland</organization>
  </responsible_party>
  <keyword>subfoveal choroidal neovascularization (CNV)</keyword>
  <keyword>age-related macular degeneration</keyword>
  <keyword>ranibizumab monotherapy</keyword>
  <keyword>combined verteporfin-therapy</keyword>
  <keyword>Lucentis® (ranibizumab)</keyword>
  <keyword>Visudyne®</keyword>
  <keyword>photodynamic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

